May 1, 2016 Issue of JAMA Oncology

May 2016, Vol 2, No. 5, Pages 559-695

Original Investigation

Emergency Department鈥揑nitiated Palliative Care in Advanced Cancer: A Randomized Clinical Trial

Corita R. Grudzen, MD, MSHS; Lynne D. Richardson, MD; Pauline N. Johnson, BS; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):591-598. doi:10.1001/jamaoncol.2015.5252

This randomized clinical trial compares quality of life of patients with advanced cancer who received emergency department鈥搃nitiated palliative care vs usual care.

Editorial
The Emergency Department Point of Palliative Care Access for Patients With Advanced Cancer
Eduardo Bruera, MD

JAMA Oncol
Editor's Note
Prospective, Interdisciplinary Randomized Clinical Trials for Patients With Cancer in the Emergency Department: A Step Forward for Palliative Oncology Care
Charles R. Thomas Jr, MD

JAMA Oncol

Associations of Oral 伪-, 尾-, and 纬-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer

Ilir Agalliu, MD, ScD; Susan Gapstur, PhD; Zigui Chen, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):599-606. doi:10.1001/jamaoncol.2015.5504

This analysis of 2 large study cohorts examines the association of incident head and neck squamous cell carcinoma with oral detection of different types of human papillomavirus.

Invited Commentary
The Alpha, Beta, Gammas of Oral Human Papillomavirus Infection and Head and Neck Cancer Risk
Dana E. Rollison, PhD; Maura L. Gillison, MD, PhD

JAMA Oncol

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

Marian H. Harris, MD, PhD; Steven G. DuBois, MD, MPH; Julia L. Glade Bender, MD; et al.

Abstract Full Text

open access has audio

JAMA Oncol. 2016;2(5):608-615. doi:10.1001/jamaoncol.2015.5689

This clinical genomics sequencing study assesses the feasibility of identifying actionable alterations and making individualized cancer therapy recommendations in pediatric patients with extracranial solid tumors.

Podcast: Molecular Profiling in Pediatric Tumors (JAMA Oncology)

Editorial
Precision Therapy for Pediatric Cancers
Javed Khan, MD; Lee J. Helman, MD

JAMA Oncol

Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors

D. Williams Parsons, MD, PhD; Angshumoy Roy, MD, PhD; Yaping Yang, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2016;2(5):616-624. doi:10.1001/jamaoncol.2015.5699

This study characterizes the diagnostic yield of combined tumor and germline whole-exome sequencing for children with solid tumors.

Editorial
Precision Therapy for Pediatric Cancers
Javed Khan, MD; Lee J. Helman, MD

JAMA Oncol

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis

Jonathan Douxfils, PharmD, PhD; Hélène Haguet, MBS; François Mullier, PharmD, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):625-632. doi:10.1001/jamaoncol.2015.5932

This systematic review and meta-analysis characterizes the risk of cardiovascular events, major molecular response, and overall survival found when BCR-ABL tyrosine kinase inhibitors were used to treat chronic myeloid leukemia.

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer

Jenny F. Seligmann, PhD; Faye Elliott, MSc; Susan D. Richman, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):633-642. doi:10.1001/jamaoncol.2015.6065

This secondary analysis of tumor samples from the PICCOLO trial investigates whether high tumor expression of either the EGFR ligand epiregulin or amphiregulin is associated with panitumumab therapy benefit in patients with RAS wild-type advanced colorectal cancer.

Editorial
AREG and EREG as Predictive Biomarkers for RAS Wild-Type Colorectal Cancer Treated With Panitumumab: A Fresh Approach to an Old Puzzle
Elizabeth C. Smyth, MB, BCh, MSc; Khurum Khan, MBBS; David Cunningham, FMedSci

JAMA Oncol

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial

Julien Taieb, MD, PhD; Aziz Zaanan, MD, PhD; Karine Le Malicot, MS; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):643-653. doi:10.1001/jamaoncol.2015.5225

The post hoc analysis of data from a trial comparing adjuvant FOLFOX with vs without cetuximab for stage III colon cancer investigates associations between BRAF and KRAS mutations in tumor samples and disease-free and overall survival.

Invited Commentary
Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon Cancer: Requirements for Accurate Prognosis Assessment
Dirk Klingbiel, PhD; Sabine Tejpar, MD, PhD

JAMA Oncol

DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial

Valérie Boige, MD, PhD; Marc Vincent, PhD; Philippe Alexandre, MS; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):655-662. doi:10.1001/jamaoncol.2015.5392

This secondary analysis of the PETACC-8 clinical trial analyzes the effect of DPYD variants on fluorouracil-related adverse events in patients with stage III colon cancer treated with a fluorouracil, leucovorin, and oxaliplatin regimen.

Invited Commentary
Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial
Steven M. Offer, PhD; Robert B. Diasio, MD

JAMA Oncol

Brief Report

Intrinsic Genomic Differences Between African American and White Patients With Clear Cell Renal Cell Carcinoma

Bhavani Krishnan, PhD; Tracy L. Rose, MD, MPH; Jordan Kardos, BS; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):664-667. doi:10.1001/jamaoncol.2016.0005

This study of 438 clear cell renal cell carcinoma (ccRCC) data sets (419 white patients and 19 African American patients) examines the racial differences in the tumor biology of ccRCC and seeks to determine racial mutation rate and gene expression differences.

Research Letter

Computed Tomographic Screening for Lung Cancer Trends at Leading Academic Medical Centers From 2013 to 2015

Phillip M. Boiselle, MD; Caroline Chiles, MD; James G. Ravenel, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):682-684. doi:10.1001/jamaoncol.2015.6419

Leading US academic medical centers were resurveyed to reassess their practices and determine whether there would be greater conformity of practice patterns and increased patient volumes in response to changes in policy and payment decisions and nodule guidelines.

Communication of Recurrence Risk Estimates to Patients Diagnosed With Breast Cancer

Brian J. Zikmund-Fisher, PhD; Nancy K. Janz, PhD; Sarah T. Hawley, PhD, MPH; et al.

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):684-686. doi:10.1001/jamaoncol.2015.6416

This survey of medical oncologists and surgeons examines how often they use informational tools and provide patients diagnosed as having breast cancer with detailed recurrence risk information, and explores what clinician characteristics influence these behaviors.

Review

Medical Marijuana Use in Oncology: A Review

Gianna Wilkie, BS; Bachir Sakr, MD; Tina Rizack, MD, MPH

Abstract Full Text

free access

JAMA Oncol. 2016;2(5):670-675. doi:10.1001/jamaoncol.2016.0155

This review discusses the history, mechanisms of action, and current data on the uses of medical marijuana in chemotherapy-induced nausea and vomiting, cancer-associated pain, and as an antitumor agent.

JAMA Oncology Clinical Challenge

Eosinophilic, Polymorphic, and Pruritic Eruption Associated With Radiotherapy on the Skin of the Right Breast

Marloes S. van Kester, MD, PhD; Koen D. Quint, MD, PhD

Abstract Full Text

JAMA Oncol. 2016;2(5):677-678. doi:10.1001/jamaoncol.2015.6596

A 72-year-old woman was treated with postoperative radiotherapy after lumpectomy of a cT1bN0M0 mammary carcinoma; 2 months later she developed pruritic, pustules and papules on the skin of the ipsilateral right breast. What is your diagnosis?

An Intraoral Mass Associated With Myelodysplastic Syndrome

James K. Mangan, MD, PhD; Milda Chmieliauskaite, DMD, MPH; Eric T. Stoopler, DMD, FDSRCS, FDSRCPS

Abstract Full Text

JAMA Oncol. 2016;2(5):679-680. doi:10.1001/jamaoncol.2016.0113

A man in his 70s with hypertension, benign prostatic hypertrophy, and myelodysplastic syndrome (MDS) presented for a second opinion regarding treatment of MDS 3 years after he had developed neutropenia and mild thrombocytopenia, fatigue, and an isolated, symptomatic polypoid mass involving his right upper labial mucosa. What is your diagnosis?

Viewpoint

Technology Spotlight

Patient-Derived Tumor Xenografts: Why Now?

Edison T. Liu, MD; Carol J. Bult, PhD; Leonard D. Shultz, PhD

Abstract Full Text

JAMA Oncol. 2016;2(5):567-568. doi:10.1001/jamaoncol.2016.0193

This Viewpoint examines the utility of patient-derived tumor xenografts in mice for assessment of cancer therapeutics and physiologic tumor features.

PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non鈥揝mall-Cell Lung Cancer

Nathan A. Pennell, MD, PhD

Abstract Full Text

JAMA Oncol. 2016;2(5):569-570. doi:10.1001/jamaoncol.2016.0040

This Viewpoint argues against programmed cell death 1 ligand 1 testing to determine the use of checkpoint inhibitors in patients with non鈥搒mall-cell lung cancer.

The Value of PD-L1 Testing in Non鈥揝mall-Cell Lung Cancer

Aaron Lisberg, MD; Edward B. Garon, MD

Abstract Full Text

JAMA Oncol. 2016;2(5):571-572. doi:10.1001/jamaoncol.2016.0043

This Viewpoint argues in favor of programmed cell death 1 ligand 1 testing to determine the use of checkpoint inhibitors in patients with non鈥搒mall-cell lung cancer.

Editorial